IDNA vs. PBE
Compare and contrast key facts about iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Invesco Dynamic Biotechnology & Genome ETF (PBE).
IDNA and PBE are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IDNA is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. It was launched on Jun 11, 2019. PBE is a passively managed fund by Invesco that tracks the performance of the Dynamic Biotech & Genome Intellidex Index (AMEX). It was launched on Jun 23, 2005. Both IDNA and PBE are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: IDNA or PBE.
Correlation
The correlation between IDNA and PBE is 0.86, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
IDNA vs. PBE - Performance Comparison
Key characteristics
IDNA:
0.20
PBE:
0.31
IDNA:
0.43
PBE:
0.56
IDNA:
1.05
PBE:
1.07
IDNA:
0.07
PBE:
0.20
IDNA:
0.76
PBE:
1.34
IDNA:
5.66%
PBE:
4.37%
IDNA:
21.03%
PBE:
18.58%
IDNA:
-68.26%
PBE:
-45.69%
IDNA:
-57.94%
PBE:
-19.74%
Returns By Period
In the year-to-date period, IDNA achieves a -0.68% return, which is significantly lower than PBE's 2.15% return.
IDNA
-0.68%
-1.61%
-4.22%
2.48%
-4.97%
N/A
PBE
2.15%
-0.62%
3.23%
3.91%
3.57%
3.42%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
IDNA vs. PBE - Expense Ratio Comparison
IDNA has a 0.47% expense ratio, which is lower than PBE's 0.59% expense ratio.
Risk-Adjusted Performance
IDNA vs. PBE - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) and Invesco Dynamic Biotechnology & Genome ETF (PBE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
IDNA vs. PBE - Dividend Comparison
IDNA's dividend yield for the trailing twelve months is around 0.98%, more than PBE's 0.05% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
PBE Invesco Dynamic Biotechnology & Genome ETF | 0.05% | 0.02% | 0.00% | 0.00% | 0.04% | 0.00% | 0.00% | 0.57% | 0.38% | 1.12% | 0.55% |
Drawdowns
IDNA vs. PBE - Drawdown Comparison
The maximum IDNA drawdown since its inception was -68.26%, which is greater than PBE's maximum drawdown of -45.69%. Use the drawdown chart below to compare losses from any high point for IDNA and PBE. For additional features, visit the drawdowns tool.
Volatility
IDNA vs. PBE - Volatility Comparison
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a higher volatility of 6.42% compared to Invesco Dynamic Biotechnology & Genome ETF (PBE) at 5.85%. This indicates that IDNA's price experiences larger fluctuations and is considered to be riskier than PBE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.